 |
 |
Delda, Jacob, Ivan and all. I can't recall seeing a letter from Upjohn that discusses its pramipexole "labeling" interactions with the FDA.(Any steer in this direction would be greatly appreciated) So the following may be redundant. Like many list subscribers, pramipexole is very effective in controlling my PD symptoms and I am therefore, like you all, very concerned about its approval and open market availability. Could Upjohn's "problem" with "Labeling" be a characteristic(s) of pramipexole that the FDA would require be disclosed on the label or on the data sheet that seemingly accompanies all perscription drugs? Could these characteristics not affect pramipexole's , in the strictest sense, medication effectiveness, but rather threaten its competitiveness/profitabilty in a market that seems to be very active with new, and purportedly promising PD meds? Could it be that the "delay" (timing) of the commercialization of pramipexole is not a result of FDA lethargy? Any knowlege, insights, or speculations are appreciated. Don Hoesterey <[log in to unmask]>